La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Medtronic Gestion
Gestion contrôle des critères 2/4
Medtronic's CEO is Geoff Martha, appointed in Apr 2020, has a tenure of 4.33 years. total yearly compensation is $20.08M, comprised of 6.7% salary and 93.3% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth $6.53M. The average tenure of the management team and the board of directors is 3.3 years and 9.6 years respectively.
Informations clés
Geoff Martha
Directeur général
US$20.1m
Rémunération totale
| Pourcentage du salaire du PDG | 6.7% |
| Durée du mandat du directeur général | 4.3yrs |
| Propriété du PDG | 0.006% |
| Durée moyenne d'occupation des postes de direction | 3.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 9.6yrs |
Mises à jour récentes de la gestion
Recent updates
Medtronic: Still A Buy Before Earnings
Aug 17Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down
Aug 08
Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential
Jul 16At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?
Jul 11Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year
Jun 27Medtronic: Why I Disagree With The Crowd
Jun 14Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's
Jun 10Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
May 27Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70
May 26These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well
May 22Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release
May 13Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?
May 0135% Undervalued? Medtronic's Future Looks Very Bright
Apr 12Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now
Mar 27Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth
Mar 11Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69
Mar 11Medtronic: Its Recent Beat Proves That It Continues To Be A Rock
Feb 25Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 22Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility
Feb 16A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Jan 31Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?
Jan 16Medtronic Stock's Rally Is Set To Continue
Jan 11Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings
Dec 29Medtronic's (NYSE:MDT) Dividend Will Be $0.69
Dec 12Medtronic: The GLP-1 Drug Headwinds Are Overblown
Dec 103.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic
Nov 28Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes
Nov 19Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings
Nov 17Medtronic Faces Potential Decline Despite Financial Strength
Oct 29An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued
Oct 19Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Oct 04Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%
Sep 27Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Sep 18Medtronic: The Tide Is Turning
Aug 24Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Aug 21Medtronic: Dark Clouds Are Clearing - Outperformance Ahead
Aug 14Return Trends At Medtronic (NYSE:MDT) Aren't Appealing
Aug 11Medtronic: Expanding Product Portfolio Without Affecting Dividend Growth
Jul 15Are Medtronic plc (NYSE:MDT) Investors Paying Above The Intrinsic Value?
Jul 09Is Medtronic (NYSE:MDT) A Risky Investment?
Jun 21Medtronic: Weak Forecasts Spoiled Strong Results For The Reporting Quarter
Jun 21Is Medtronic's Dividend In A Good Place?
Jun 14Medtronic (NYSE:MDT) Is Increasing Its Dividend To $0.69
Jun 03Medtronic: Solid Q4 Earnings, Don't Fret About Guidance
May 26Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Apr 26 2024 | US$20m | US$1m | US$4b |
| Jan 26 2024 | n/a | n/a | US$4b |
| Oct 27 2023 | n/a | n/a | US$4b |
| Jul 28 2023 | n/a | n/a | US$4b |
| Apr 28 2023 | US$15m | US$1m | US$4b |
| Jan 27 2023 | n/a | n/a | US$4b |
| Oct 28 2022 | n/a | n/a | US$4b |
| Jul 29 2022 | n/a | n/a | US$5b |
| Apr 29 2022 | n/a | n/a | US$5b |
| Jan 28 2022 | n/a | n/a | US$5b |
| Oct 29 2021 | n/a | n/a | US$5b |
| Jul 30 2021 | n/a | n/a | US$4b |
| Apr 30 2021 | US$18m | US$1m | US$4b |
| Jan 29 2021 | n/a | n/a | US$3b |
| Oct 30 2020 | n/a | n/a | US$4b |
| Jul 31 2020 | n/a | n/a | US$4b |
| Apr 24 2020 | US$6m | US$905k | US$5b |
| Jan 24 2020 | n/a | n/a | US$5b |
| Oct 25 2019 | n/a | n/a | US$5b |
| Jul 26 2019 | n/a | n/a | US$4b |
| Apr 26 2019 | US$4m | US$693k | US$5b |
Rémunération vs marché: Geoff's total compensation ($USD20.08M) is above average for companies of similar size in the US market ($USD13.21M).
Rémunération et revenus: Geoff's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
PDG
Geoff Martha (54 yo)
4.3yrs
Titularisation
US$20,084,630
Compensation
Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Director of NextEra...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.3yrs | US$20.08m | 0.0060% $ 6.5m | |
| Executive VP & President of Cardiovascular Portfolio | no data | US$6.55m | 0.0021% $ 2.3m | |
| Executive VP & President of Neuroscience Portfolio | 4.8yrs | US$6.44m | 0.00092% $ 998.3k | |
| Executive Vice President of Global Operations & Supply Chain | 3.3yrs | US$7.66m | 0.0015% $ 1.6m | |
| Senior Vice President of Global Financial Planning and Analysis & Interim CFO | no data | pas de données | 0.00045% $ 488.3k | |
| Senior Vice President of Global Operations and Business Services | 7.8yrs | pas de données | pas de données | |
| Senior VP | 3.2yrs | pas de données | 0.0022% $ 2.4m | |
| Senior VP and Chief Technology & Innovation Officer | 1.2yrs | pas de données | pas de données | |
| Senior VP and Chief Scientific & Medical Officer | 2.3yrs | pas de données | pas de données | |
| VP & Head of Investor Relations | 9.2yrs | pas de données | pas de données | |
| Executive VP | 2.5yrs | US$11.72m | 0.0019% $ 2.1m | |
| Senior VP & Chief Communications Officer | 3.6yrs | pas de données | pas de données |
3.3yrs
Durée moyenne de l'emploi
59yo
Âge moyen
Gestion expérimentée: MDT's management team is considered experienced (3.3 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.8yrs | US$20.08m | 0.0060% $ 6.5m | |
| Independent Director | 11.6yrs | US$365.06k | 0.0012% $ 1.3m | |
| Independent Director | 17.6yrs | US$350.06k | 0.0015% $ 1.6m | |
| Independent Director | 9.6yrs | US$385.06k | 0.0034% $ 3.6m | |
| Lead Independent Director | 9.6yrs | US$410.06k | 0.0028% $ 3.1m | |
| Independent Director | 24.6yrs | US$375.06k | 0.0031% $ 3.3m | |
| Independent Director | 5.4yrs | US$370.06k | 0.00048% $ 520.8k | |
| Independent Director | 10.6yrs | US$370.06k | 0.0010% $ 1.1m | |
| Independent Director | 2.2yrs | US$350.06k | 0.00012% $ 130.2k | |
| Independent Director | 3.9yrs | US$370.06k | 0.00032% $ 347.2k | |
| Independent Director | 1.2yrs | US$306.97k | 0% $ 0 |
9.6yrs
Durée moyenne de l'emploi
64yo
Âge moyen
Conseil d'administration expérimenté: MDT's board of directors are considered experienced (9.6 years average tenure).